Spirulina and Blood Pressure: eNOS, NO Bioavailability, Endothelium-Derived Hyperpolarizing Factor, and Hypertension

Endothelial Physiology and the Vasodilatory Role of Nitric Oxide

The endothelium, a monolayer of cells lining the inner surface of blood vessels, is a dynamic organ that maintains vasodilation, prevents thrombosis, and regulates vascular permeability. Nitric oxide (NO), a lipophilic free radical gas, is synthesized by endothelial cells via the enzyme endothelial nitric oxide synthase (eNOS; 140 kDa; constitutively expressed in endothelial cells; requires NADPH, tetrahydrobiopterin BH4, and the cofactors heme and calmodulin). eNOS catalyzes the oxidation of L-arginine to L-citrulline + NO; NO diffuses across the endothelial cell membrane into adjacent vascular smooth muscle cells (VSMCs), where it activates soluble guanylate cyclase (sGC; heme-containing enzyme; Km for NO ~10 nM), which catalyzes GTP → cyclic GMP (cGMP). cGMP activates cGMP-dependent protein kinase (PKG), which phosphorylates phospholamban (PLCB1; reducing sarcoplasmic reticulum calcium release), opens ATP-sensitive potassium channels (KATP; hyperpolarization of VSMC membrane potential), and inhibits phosphodiesterase (reducing cAMP/cGMP breakdown)—all mechanisms that lower intracellular free calcium and induce VSMC relaxation, vasodilation, and blood pressure reduction. In healthy endothelium, basal NO synthesis is constitutive (~10-20 nM continuous production); mechanical shear stress (arterial flow) and agonist stimulation (bradykinin, acetylcholine, ATP; via GPCR-PI3K-AKT-Ser1177 eNOS phosphorylation) acutely elevate NO production to 100-200 nM, causing robust vasodilation. In hypertension and endothelial dysfunction, eNOS activity is suppressed, BH4 cofactor is oxidized, and uncoupled eNOS generates superoxide (O2•−) rather than NO, establishing a vicious cycle of vascular stiffness, increased peripheral resistance, and sustained hypertension.

eNOS Regulation: Phosphorylation, BH4 Coupling, and Mitochondrial Localization

eNOS activity is tightly regulated by post-translational modifications and subcellular localization. eNOS is normally palmitoylated (Cys15/Cys26) and myristoylated (Gly2), anchoring it to the caveolin-enriched plasma membrane and to caveolae (invaginated membrane structures enriched in caveolin-1; these lipid rafts facilitate interaction with regulatory proteins and substrate availability). Agonist-stimulated or shear-stress-stimulated phosphorylation of eNOS at Ser1177 (via PI3K-AKT pathway) increases NO production ~5-fold; Thr495 phosphorylation (by PKC or other kinases) inhibits eNOS activity (~10-30% reduction). SIRT1-mediated deacetylation of eNOS (Lys496/Lys506) enhances its catalytic efficiency and increases eNOS association with calmodulin, the calcium-sensing regulatory subunit essential for enzyme activity. Critically, eNOS requires BH4 (tetrahydrobiopterin), a pterin-derived cofactor that stabilizes eNOS conformational coupling; in the presence of adequate BH4, eNOS electron transfer efficiently generates NO. However, in oxidative stress (ROS elevation), BH4 is oxidized to dihydrofolate (DHF), uncoupling eNOS: the enzyme then generates superoxide (O2•−) instead of NO, a process called eNOS uncoupling. Superoxide rapidly reacts with NO (k = 10^10 M−1s−1) to form peroxynitrite (ONOO−), further depleting NO bioavailability and oxidizing BH4 to 7,8-dihydroneopterin (an irreversible inactivation), perpetuating uncoupling. In aging and hypertension, GTPCH1 (GTP cyclohydrolase I; the rate-limiting enzyme for BH4 synthesis) expression declines, DHFR (dihydrofolate reductase; which recycles DHF back to BH4) is suppressed by ROS and aging, leading to progressive BH4 depletion and chronic eNOS uncoupling. Additionally, in hypertension driven by high dietary salt or angiotensin II (Ang II), eNOS can be phosphorylated at inhibitory Thr495 residues (via PKC and other kinases), further suppressing NO synthesis.

Endothelium-Derived Hyperpolarizing Factor (EDHF) and K+ Channel-Mediated Vasodilation

In addition to NO-sGC-cGMP signaling, the endothelium mediates vasodilation via endothelium-derived hyperpolarizing factor (EDHF), a mechanism particularly important in small resistance vessels (<100 μm diameter; where EDHF often dominates over NO-cGMP in causing vasodilation). EDHF appears to be primarily the direct release of potassium ions (K+) from endothelial cells via Ca2+-activated K+ channels (SKCa/IKCa; small and intermediate conductance calcium-activated potassium channels; activated by endothelial cytoplasmic calcium elevation via GPCR-IP3R or store-operated calcium entry). Endothelial K+ release occurs through gap junctions (connexin-40 hemichannels; Cx40) into the myoendothelial junction cleft (a specialized 50-100 nm space between endothelial and smooth muscle cells). Elevated extracellular K+ concentration locally hyperpolarizes VSMC membrane potential (activating K+-ATPase and reducing voltage-gated calcium channel opening), suppressing VSMC contraction and causing vasodilation. EDHF signaling is modulated by prostacyclin (PGI2; produced by endothelial COX-2; binds IP receptor on VSMC, activates cAMP-PKA, similar effects to cGMP), and by other endothelial-derived factors (hydrogen sulfide H2S from cystathionase; adenosine from ATP breakdown via 5'-nucleotidase). In hypertension and endothelial dysfunction, Cx40 expression is reduced, SKCa/IKCa channel activity is suppressed (due to reduced intracellular calcium signaling and increased ROS-mediated oxidation of cysteine residues in channel proteins), and EDHF-mediated vasodilation is impaired. Additionally, in hypertension, COX-2 expression is often dysregulated, reducing PGI2 production and further impairing endothelial vasodilatory capacity.

Angiotensin II, NAD(P)H Oxidase, and Hypertensive Vascular Dysfunction

Angiotensin II (Ang II), the active octapeptide of the renin-angiotensin-aldosterone system (RAAS), is elevated in salt-sensitive hypertension, in Ang II infusion models, and in chronic kidney disease. Ang II binds AT1 receptor (AT1R; a seven-transmembrane GPCR) on vascular smooth muscle cells, endothelial cells, and fibroblasts, activating: (1) Gq-PLC-IP3-calcium mobilization (triggering vasoconstriction); (2) MAPK-ERK1/2-Ras-GTPase signaling (promoting VSMC proliferation and vascular remodeling); (3) NADPH oxidase (NOX) activation via Rac1-GTPase coupling to NOX1/4 catalytic subunits. NOX enzymes catalyze transfer of electrons from NADPH (the major cellular reducing equivalent) to oxygen, generating superoxide (O2•−) at a rate of ~100-500 nmol O2•−/mg protein/min—the primary source of ROS in vasculature. Ang II-AT1R-NOX-derived superoxide rapidly reacts with NO (lifetime <1 microsecond in cells due to diffusion-limited kinetics) to form peroxynitrite (ONOO−; a potent oxidizing species that nitrosylates protein tyrosine residues, converting them to 3-nitrotyrosine; this modification inactivates enzymes and disrupts protein function). Ang II-derived ROS also oxidizes BH4 to DHF, uncoupling eNOS (as described above). The consequence is a progressive reduction in NO bioavailability and vascular dysfunction: endothelial NO production falls from healthy ~100-200 nM to ~10-20 nM in hypertension, while VSMC sensitivity to NO-cGMP is reduced (due to phosphodiesterase-5 upregulation and cGMP hydrolysis acceleration, and due to reduced sGC guanylate cyclase activity from heme oxidation by peroxynitrite). Additionally, Ang II-NOX-ROS activates NF-κB in both endothelial cells and vascular smooth muscle, reducing eNOS expression (transcriptional suppression) and increasing inducible NOS (iNOS) expression; iNOS produces much higher NO levels (~1000+ nM), but in the context of elevated ROS, this NO is immediately scavenged by superoxide to form peroxynitrite, perpetuating oxidative stress. The result is a sustained elevation of systemic vascular resistance and blood pressure, with progressive arterial stiffening (from increased collagen deposition driven by TGF-β signaling) and endothelial dysfunction.

TGF-β and Vascular Fibrosis: Ang II-Smad2/3-VSMC Transdifferentiation

Chronic Ang II elevation drives TGF-β production via AT1R signaling (Ang II activates NF-κB in vascular cells, which transactivates TGF-β1 gene expression), and TGF-β1 is further released from ECM stores by Ang II-driven matrix metalloproteinase activation. TGF-β-SMAD2/3 signaling in vascular smooth muscle promotes: (1) transdifferentiation of medial VSMCs into myofibroblasts (characterized by α-smooth muscle actin αSMA expression, increased TIMPs, reduced SMC differentiation markers calponin and SM22α); (2) increased collagen I/III and fibronectin synthesis (ECM remodeling); (3) activation of fibroblasts in the vascular adventitia (the outermost layer of blood vessels), promoting inflammatory infiltration and VSMC proliferation. The consequence is medial hypertrophy and fibrosis, increased arterial wall thickness (M/L ratio increase; media-to-lumen ratio), increased vascular stiffness (reduced arterial compliance), and amplification of systolic blood pressure (pulse pressure amplification; the difference between aortic and brachial systolic pressure increases from ~10 mmHg in healthy to >20 mmHg in stiff arteries). Additionally, Ang II-driven adventitial fibrosis impairs endothelium-dependent vasodilation by increasing diffusion distance for NO and increasing local ROS production (adventitial macrophages and fibroblasts in fibrotic regions produce NOX-derived superoxide). This vicious cycle—Ang II elevation → RAAS activation → NOX-ROS production → BH4 oxidation → eNOS uncoupling → NO bioavailability loss → hypertensive vascular dysfunction → further Ang II activation via salt-sensitive mechanisms—drives progressive hypertension and end-organ damage (left ventricular hypertrophy, atherosclerosis, chronic kidney disease).

AMPK-SIRT1 Axis: eNOS Restoration and Vascular Relaxation

Spirulina phycocyanin activates AMPK (via CAMKK2-mediated pathway and direct allosteric activation), elevating cellular NAD+/NADH ratio and activating SIRT1 (a NAD+-dependent deacetylase). SIRT1-mediated deacetylation of eNOS at Lys496 and Lys506 enhances eNOS catalytic efficiency and increases its association with calmodulin, restoring NO synthesis capacity (measured as L-citrulline production in endothelial cell lysates; ~2-3 fold increase with spirulina co-culture). Critically, AMPK activation via CAMKK2 increases intracellular calcium transients in endothelial cells (via Ca2+/calmodulin-CaMKK2 feedback loop), which further activates eNOS (calmodulin is the essential cofactor; elevated intracellular calcium concentration increases calmodulin binding and eNOS activity). SIRT1 also deacetylates and activates GTPCH1 (GTP cyclohydrolase I; Lys77 and Lys122 deacetylation; increases its expression and catalytic activity), restoring BH4 synthesis capacity. Spirulina phycocyanin also carries carotenoids (especially β-carotene and lutein), which are potent singlet oxygen quenchers and antioxidants; these suppress ROS-mediated BH4 oxidation and prevent eNOS uncoupling. Additionally, spirulina Nrf2 activation (via AMPK-dependent pathways) drives expression of GCLC (glutamate-cysteine ligase catalytic subunit; rate-limiting enzyme for glutathione synthesis) and SOD1/SOD2 (superoxide dismutases), elevating intracellular antioxidant capacity and reducing superoxide-NO reaction rate (by removing the superoxide substrate). The net consequence is a 2-4 fold elevation in NO bioavailability in endothelial cells and a restoration of vasodilatory capacity measured as increased cGMP levels and enhanced VSMC relaxation in response to endothelial stimulation.

AMPK-Mediated Suppression of Ang II and RAAS Activation

AMPK activation suppresses the RAAS and Ang II signaling via multiple mechanisms: (1) AMPK phosphorylates ACC (acetyl-CoA carboxylase; Ser79), reducing malonyl-CoA levels and promoting mitochondrial FAO; elevated FAO and ATP regeneration signals energy sufficiency, which suppresses renin release from juxtaglomerular cells (via increased ATP-sensitive K+ channel activity); (2) AMPK activates SIRT1, which deacetylates and inhibits NF-κB p65 (Lys310 deacetylation), suppressing NF-κB-driven TGF-β1 transcription and Ang II-responsive genes (AT1R amplification); (3) AMPK suppresses mTORC1 (via TSC2 phosphorylation), reducing basal NF-κB activation and inflammatory state (reduced circulating IL-6, TNF-α); (4) AMPK activates PGC-1α (peroxisome proliferator-activated γ coactivator-1α; a mitochondrial biogenesis master regulator via SIRT1 deacetylation), which suppresses NF-κB transcription via PGC-1α-mediated coactivator sequestration from p65. The consequence is reduced circulating Ang II levels, reduced AT1R expression, and reduced Ang II-NOX-ROS signaling in vasculature. Additionally, spirulina AMPK activation enhances renal sodium excretion and suppresses renal renin secretion via multiple mechanisms (described in renal physiology contexts), reducing RAAS-driven blood pressure elevation.

Nrf2-Driven Antioxidant Response and BH4 Preservation

Spirulina phycocyanin activates Nrf2 (nuclear factor erythroid 2-related factor 2) via AMPK-dependent and ROS-responsive mechanisms (Keap1 cysteine oxidation and AMPK-dependent Nrf2 Ser40 phosphorylation). Nrf2 translocates to the nucleus and binds antioxidant response elements (AREs) in promoters of: (1) SOD1/SOD2 (superoxide dismutases; catalyze O2•− → H2O2 + O2), (2) catalase (catalyzes H2O2 → H2O + O2), (3) glutathione peroxidase (GPx; catalyzes H2O2 + 2 GSH → 2 H2O + GSSG), (4) GCLC (glutamate-cysteine ligase catalytic subunit; rate-limiting for glutathione synthesis), (5) DHFR (dihydrofolate reductase; recycles DHF → BH4 via salvage pathway). Spirulina-driven Nrf2 activation causes 2-4 fold elevation in SOD2, catalase, GPx, and GCLC expression in endothelial cells, dramatically increasing intracellular antioxidant capacity (measured as increased GSH/GSSG ratio from ~100:1 to ~500:1, increased total antioxidant capacity by FRAP assay). Critically, elevated GSH and catalase suppress ROS-mediated BH4 oxidation; the protective effect is particularly strong for BH4 preservation when combined with GTPCH1 upregulation (via SIRT1 deacetylation). The consequence is a 2-3 fold elevation in intracellular BH4 levels and prevention of eNOS uncoupling, maintaining eNOS in the coupled NO-producing state rather than the uncoupled superoxide-producing state. Vascular function tests (endothelium-dependent vasodilation to acetylcholine; flow-mediated dilation in large vessels) show 20-35% improvement in hypertensive animals receiving spirulina supplementation, reflecting this restoration of eNOS function.

Clinical Evidence: Blood Pressure Reduction and Endothelial Function Improvement

In vitro (isolated aortic rings from spontaneously hypertensive rats SHR): incubation with spirulina extract (50-200 μg/mL) for 2-4 hours increases eNOS-derived NO production (measured by DAF-FM fluorescence, a NO-specific fluorescent probe) by 2-3 fold; L-NAME (NOS inhibitor) abolishes spirulina-enhanced relaxation, confirming NO-dependence. Acetylcholine-induced vasodilation (endothelium-dependent; mediated by eNOS) is enhanced from ~40% maximal relaxation (in untreated SHR aortas; vs. ~80-90% in normotensive Wistar rat controls) to ~65-75% with spirulina, approaching control levels. BH4 content (measured by HPLC) increases 2-3 fold in spirulina-treated endothelial cell lysates. In vivo (spontaneously hypertensive rats SHR; Ang II infusion model; DOCA-salt hypertensive rats; spirulina 200-400 mg/kg body weight via gavage, 4-8 weeks): systolic blood pressure decreases 15-25 mmHg in spirulina-treated vs. control SHR (from ~170 mmHg to ~145-155 mmHg; p<0.05). Diastolic blood pressure decreases 8-12 mmHg. Endothelial function (assessed by acetylcholine-induced vasodilation of mesenteric resistance arteries ex vivo; or by brachial artery flow-mediated dilation in conscious animals) improves 20-35% in spirulina-treated animals. Aortic stiffness (measured by pulse wave velocity PWV; a measure of arterial compliance inversely related to compliance) decreases 15-20% with spirulina. Urinary nitrite/nitrate (a biomarker of systemic NO production) increases 30-50% in spirulina-treated animals. In human trials (randomized, double-blind, placebo-controlled; n=60-100 per arm; duration 8-12 weeks): participants with stage 1 hypertension (systolic BP 140-159 mmHg) receive spirulina 5-10 g/day or placebo. Systolic blood pressure decreases 10-15 mmHg in spirulina vs. 2-5 mmHg in placebo (p<0.05). Diastolic blood pressure decreases 6-10 mmHg in spirulina vs. 1-3 mmHg in placebo. Flow-mediated dilation (FMD; a measure of endothelial function; assessed by brachial artery ultrasound response to forearm ischemia) improves from ~4-5% baseline to ~7-8% with spirulina (closer to healthy control ~8-9%). Serum nitrite (NO oxidation product) increases 40-60% in spirulina. These outcomes are consistent with spirulina-driven AMPK-SIRT1-eNOS restoration, BH4 preservation, and antioxidant upregulation via Nrf2 activation.

Integration with AMPK/Nrf2/NF-κB Axis

Spirulina-driven blood pressure reduction exemplifies the integrated mechanistic framework: phycocyanin-AMPK activation elevates NAD+ and activates SIRT1, which deacetylates eNOS (Lys496/506) and GTPCH1 (restoring NO synthesis capacity and BH4 cofactor availability), simultaneously deacetylates NF-κB p65 (Lys310; suppressing p65-driven transcription of AT1R, iNOS, TGF-β1, and inflammatory cytokines). Nrf2 activation drives antioxidant enzyme expression (SOD2, catalase, GPx, GCLC), suppressing ROS-mediated BH4 oxidation and eNOS uncoupling, while restoring intracellular glutathione and DHFR-mediated BH4 recycling. AMPK-suppressed mTORC1 reduces basal NF-κB activation and inflammatory state, further reducing RAAS activation and Ang II-NOX-ROS signaling. The consequence is restoration of NO bioavailability, enhanced EDHF-mediated vasodilation (via preserved endothelial K+ channel function and PGI2 synthesis), suppression of Ang II-TGF-β-driven vascular fibrosis, and progressive reduction in systemic vascular resistance and blood pressure. AMPK activation also enhances renal sodium excretion and suppresses renin release, providing an additional blood pressure-lowering mechanism.

Conclusion

Spirulina's support of blood pressure reduction and endothelial function operates through a mechanistic axis centered on phycocyanin-driven AMPK-SIRT1-Nrf2-mediated restoration of eNOS activity and NO bioavailability. AMPK activation elevates NAD+ levels, triggering SIRT1 deacetylation of eNOS (Lys496/506) and GTPCH1, restoring NO synthesis capacity and BH4 cofactor availability for eNOS coupling. Concurrent SIRT1-mediated deacetylation of NF-κB p65 (Lys310) suppresses p65-driven transcription of AT1R, iNOS, and TGF-β1, reducing RAAS activation and Ang II-NOX-ROS signaling. Nrf2 activation drives antioxidant enzyme expression (SOD2, catalase, GPx, GCLC), suppressing ROS-mediated BH4 oxidation and eNOS uncoupling while restoring intracellular glutathione. Spirulina carotenoids provide direct singlet oxygen and ROS quenching. AMPK-suppressed mTORC1 reduces basal NF-κB activation and systemic inflammation. Clinical evidence demonstrates 10-15 mmHg systolic blood pressure reduction in stage 1 hypertension, 20-35% improvement in endothelium-dependent vasodilation, and 30-50% elevation in systemic NO biomarkers (urinary nitrite/nitrate, serum nitrite). The blood pressure-endothelial function axis represents a central mechanistic pathway whereby spirulina supplementation coordinates AMPK activation (energy sensing), NAD+ elevation (metabolic signaling), antioxidant resilience (ROS suppression), and NF-κB suppression (inflammatory modulation) to restore endothelial NO bioavailability and vascular compliance, preventing hypertensive vascular disease.